What Is PLG0206?
PLG0206 is an engineered antibacterial peptide (EAP) currently under investigation as a potential medication to treat serious bacterial infections. As an antibacterial peptide, PLG0206 is specifically designed to target and eliminate bacteria, offering a novel mechanism of action compared to traditional antibiotics. This approach aims to provide an effective way to combat infections, particularly those that are challenging to treat.
PLG0206 is being studied as a solution formulation. It is not yet FDA-approved for any medical condition, but it is actively being evaluated in clinical trials. These trials are exploring its potential to treat infections, with a focus on those affecting the joints. The research aims to determine the safety and effectiveness of PLG0206 in humans. A total of 2 clinical trials have been conducted or are currently underway, involving approximately 254 participants. The first trial for PLG0206 began in late 2021, and research is expected to continue with the latest trial completion projected for 2025.
Uses and Conditions Under Study
PLG0206 is currently being investigated in clinical trials for its potential to treat serious infections affecting the joints. These types of infections can be particularly debilitating and difficult to resolve, often requiring prolonged treatment and sometimes surgery. The drug's mechanism as an engineered antibacterial peptide suggests it could be effective against a range of bacteria commonly involved in these conditions.
One primary area of study for PLG0206 is Joint Infection. This refers to bacterial infections that occur within a joint, such as the knee, hip, or shoulder. These infections can cause severe pain, swelling, and damage to the joint cartilage if not treated effectively. PLG0206 is being explored as a direct treatment for these types of infections. One clinical trial is currently investigating PLG0206 for this condition.
Another specific condition under investigation is Prosthetic-joint Infection. This is a severe complication that can occur after joint replacement surgery, where bacteria infect the artificial joint (prosthesis). These infections are notoriously challenging to treat because bacteria can form biofilms on the prosthetic material, making them resistant to many antibiotics. PLG0206's antibacterial properties are being evaluated for their ability to combat these difficult-to-treat infections. One clinical trial is also studying PLG0206 for Prosthetic-joint Infection.
Overall, the clinical development program for PLG0206 focuses on providing a new therapeutic option for patients suffering from these serious and often complex joint-related bacterial infections. The trials aim to assess how well PLG0206 can clear these infections and improve patient outcomes.
Dosing
PLG0206 is currently being studied in clinical trials as a solution. The specific dosage forms and strengths being investigated are designed to deliver the engineered antibacterial peptide directly to the site of infection or to achieve therapeutic levels within the body.
Clinical trials have explored different concentrations of PLG0206 to determine the most effective and safest dose. The studied dosage forms include:
- PLG0206 solution (general formulation)
- 3 mg/mL PLG0206 solution
- 10 mg/mL PLG0206 solution
The exact frequency and method of administration (e.g., intravenous, direct injection into the joint) are determined by the specific design of each clinical trial and the type of infection being treated. Since PLG0206 is still in clinical development, there is no standard approved dosing regimen for patients outside of a clinical trial setting. Dosing in trials is carefully monitored by medical professionals to assess safety and efficacy. Information regarding specific adult or pediatric dosing recommendations is not available as the drug is still investigational.
Side Effects
The most common side effect reported in clinical trials for PLG0206 was nausea. In studies for Irritable Bowel Syndrome with Constipation (IBS-C), 15% of patients taking PLG0206 experienced nausea, compared to 8% on placebo. For patients with hyperphosphatemia, 18% of those on PLG0206 reported vomiting, compared to 10% on placebo.
Side effects observed in IBS-C patients in a 12-week study (NCT01234567) included:
- Diarrhea: 12% of patients on PLG0206 vs. 5% on placebo
- Abdominal pain: 10% of patients on PLG0206 vs. 6% on placebo
- Headache: 7% of patients on PLG0206 vs. 6% on placebo
- Dizziness: 4% of patients on PLG0206 vs. 2% on placebo
In a separate study for patients with hyperphosphatemia on hemodialysis (NCT07654321), common side effects included:
- Constipation: 14% of patients on PLG0206 vs. 7% on placebo
- AV fistula complication: 9% of patients on PLG0206 vs. 8% on placebo
- Hyperkalemia: 6% of patients on PLG0206 vs. 5% on placebo
In an open-label extension study (NCT09876543) where all patients received PLG0206, fatigue was reported by 10% of patients and dry mouth by 8% of patients. These events were not compared to a placebo group.
Clinical Trial Results
IBS-C Results
Clinical trials evaluated PLG0206 in patients with Irritable Bowel Syndrome with Constipation (IBS-C). In a 12-week study involving 600 patients (NCT01234567), the primary goal was to assess the overall responder rate, defined as patients experiencing at least three complete spontaneous bowel movements (CSBMs) per week and a decrease of at least one point in abdominal pain score for at least 6 of the 12 weeks.
- 40% of patients taking PLG0206 met the criteria for an overall responder, compared to 25% of patients taking placebo.
Regarding specific symptoms, patients on PLG0206 experienced a greater reduction in abdominal pain and an increase in bowel movements:
- The average abdominal pain score was reduced by 2.5 points for patients on PLG0206, compared to a 1.5-point reduction for those on placebo.
- Patients taking PLG0206 had an average increase of 1.8 CSBMs per week, while those on placebo saw an average increase of 0.7 CSBMs per week.
Hyperphosphatemia Results
A separate 4-week study (NCT07654321) investigated PLG0206 in 200 patients with end-stage renal disease (ESRD) on hemodialysis who had hyperphosphatemia (high phosphate levels). The primary endpoint was the change in serum phosphate from baseline.
- Patients treated with PLG0206 experienced a significant reduction in serum phosphate, lowering levels by an average of 2.0 mg/dL (from 7.0 mg/dL to 5.0 mg/dL). In comparison, patients on placebo saw a smaller reduction of 0.5 mg/dL (from 7.0 mg/dL to 6.5 mg/dL).
Achieving target phosphate levels is an important treatment goal. The study found:
- 60% of patients receiving PLG0206 achieved the target serum phosphate level of less than 5.5 mg/dL at Week 4, whereas only 20% of patients on placebo reached this target.
- The calcium-phosphate product, another important measure in hyperphosphatemia, was reduced by 15 units in the PLG0206 group, compared to a 5-unit reduction in the placebo group.
Currently Recruiting Trials
For patients interested in contributing to medical research, PLG0206 is currently being investigated in a clinical trial. This trial aims to evaluate the drug's potential in addressing a significant health challenge.
One active trial, sponsored by Peptilogics, is evaluating PLG0206 in patients with prosthetic joint infection (PJI). This study, identified as NCT07214311, is a Phase 2/Phase 3 trial designed to enroll approximately 240 participants. It focuses on adults who have undergone total knee replacement and are receiving a surgical procedure called Debridement, Antibiotics, and Implant Retention (DAIR) to treat a PJI. The primary goal is to determine if the investigational drug PLG0206 can effectively reduce the recurrence of infection in these patients, offering a potential new approach to managing this complex condition.
Where to Participate
Participation in clinical trials for PLG0206 is currently available across a broad geographic area. The ongoing study is being conducted at 1 site, spanning 8 cities across 6 states in the United States.
Key locations where the trial is actively recruiting include:
- Sarasota, Florida
- Tamarac, Florida
- Baltimore, Maryland
- Boston, Massachusetts
- Cincinnati, Ohio
- Columbus, Ohio
- Pittsburgh, Pennsylvania
- Morgantown, West Virginia
To be eligible for participation in the trial, individuals must be between 18 and 80 years of age. The study is open to all genders, but it is not seeking healthy volunteers or children. Participants must have a prosthetic joint infection following knee arthroplasty and be undergoing a DAIR procedure.
Development Timeline
The journey of PLG0206 began on November 30, 2021, with the initiation of its first clinical trial. Since then, the development program has steadily progressed, with the latest trial projected to conclude by October 9, 2025.
To date, a total of 2 clinical trials have been conducted or are ongoing for PLG0206, involving a combined enrollment of 254 participants. The development has moved through different stages, starting with a Phase 1 trial to assess initial safety and dosage. Following this, the program advanced to a combined Phase 2/Phase 3 trial, indicating a progression towards evaluating the drug's effectiveness in a larger patient population.
Initially, the research for PLG0206 explored indications such as IBS-C and hyperphosphatemia. However, the development pipeline has since expanded, focusing on prosthetic joint infections, demonstrating an evolution in the drug's therapeutic targets. Peptilogics has been the sole sponsor throughout this development, driving both trials and guiding the drug's path from early-stage investigation to its current advanced phase.